Immune Cell Tests | Cancer Test
Know Your Immune Health | Know Your Cancer Risk
Immune Cell Tests | Cancer Tests: There were an estimated 15 million new cancer cases around the globe each year, with 7.4 million being male and 6.7 million being female. This number is expected to increase to 25 million by 2035.
- Lung cancer is the most common cancer worldwide contributing to nearly 15% of the total number of new cases.
- Breast cancer (women only) is the second most common cancer with nearly 2 million new cases.
- Colorectal cancer was the third most common cancer with nearly 1.5 million new cases.
This growing cancer burden, within the overall context of non-communicable diseases (NCDs), in an ongoing key focus to governments, researchers and medical professionals around the world.
ImmuneCells21 has a focus to offer the most up-to-date approaches to accessing cancer risk, early detection of cancer, diagnosis of cancer, immunotherapy success, targeting of cancer treatments and monitoring reoccurrence rates of cancer.
We offer a range of individualized tests from a world-class molecular oncology laboratory. These tests can:
- Measure your immune cells activity & cytotoxicity
- Detect early signs of a developing cancer
- Help to monitor existing cancers
- Produce an individual profile of which cancer drugs and which natural substances can be used to achieve the best treatment outcomes
Key Immune Cell Function & Cancer Tests:
Natural killer cells within our bodies have the ability to detect when other cells have undergone tumor transformation and destroy those transformed cancer cells. NK cells have the ability to identify and to eliminate cancer cells, pathogens, including viruses with high efficiency. As humans we have an average level of NK activity which is regarded as healthy, low functioning NK activity is associated with higher risks of cancer and lower immune protection.
A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A CA biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Different types of cancers release different substances which can be identified and measured from a simple blood sample. During cancer treatments tumor markers can be used as a one monitoring aspect.
CTCs are cancer cells which have broken away from the primary tumor and have entered the blood stream where they circulate and have the potential to generate metastatic disease. The CTC test provides information about the presence of Circulating Tumor Cells, their concentration and immunophenotype, which may help identify their origin.
This test provides information about the efficacy of specific drugs on cancer cells derived from a single patient. The method incorporates two procedures, epigenetic analysis and viability assays to validate the data.
This test examines the efficacy of natural biological substances or extracts on cancer cells. This assessment is based on three methods: the direct cytotoxic effect, stimulation of the immune system and the inhibition of proliferative signals in the cancer cells.